Premium
The efficacy of combination of induction chemotherapy and irreversible electroporation ablation for patients with locally advanced pancreatic adenocarcinoma
Author(s) -
Huang KaiWen,
Yang PoChih,
Pua Uei,
Kim ManDeuk,
Li ShengPing,
Qiu YuDong,
Song TianQiang,
Liang PoChin
Publication year - 2018
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.25110
Subject(s) - irreversible electroporation , medicine , gemcitabine , chemotherapy , pancreatic cancer , surgery , regimen , oncology , tegafur , progression free survival , electroporation , urology , cancer , biochemistry , chemistry , gene
Background and Objectives Irreversible electroporation (IRE) is a non‐thermal focal therapy that utilizes high voltage electric pulses to permanently rupture the cellular membrane and induce cell death. In this multi‐center study, we evaluated the safety and efficacy of IRE in patients with locally advanced pancreatic cancer (LAPC). Methods From 2012 to 2015, we performed laparotomic and laparoscopic IRE in a total of 70 patients with stage III LAPC. Either gemcitabine‐based or TS‐1 (Tegafur, Gimeracil, and Oteracil) chemotherapy was applied for at least 3 months before the IRE. Results No IRE‐related deaths occurred. A median follow‐up of 28.1 months showed that six patients (8.6%) experienced local recurrence and 24 (34%) experienced distant progression. The overall median survival from the time of treatment was 22.6 months, and the progression‐free survival (PFS) was 15.4 months. The overall survival in the patients who used gemcitabine‐based reagents was 19.1 months and that of those who used TS‐1 was 28.7 months. The PFS for these two groups were 13.2 months and 26.4 months; the difference is significant. Conclusions Our study suggests that IRE is safe and effective for the control of LAPC. We surmise that the addition of IRE to a chemotherapy regimen may provide a survival advantage.